immatics biotechnologies GmbH today announced that the company obtained European patent protection for the composition of matter for its drug candidate IMA901. Patent no. EP1760089 will protect the set of the peptides that form the core of the pharmaceutical compositions of IMA901. The company's lead product is in Phase II trials in renal cancer patients.
Patent EP1794190 will cover an additional MHC-Class II peptide. Both patents add to the broad IP portfolio of immatics.
Further expanding its patent portfolio covering other products, immatics has been granted US patent 7,528,224 covering a peptide encoded by the MUC-1 gene; this peptide is able to elicit an immune response against tumors overexpressing MUC-1. immatics has already obtained patent protection for this peptide in Europe.
"The first TUMAP patent owned by immatics was granted in 2004 and patent protection for peptide sequences has remained unchallenged in all major pharma markets including North America, EU, and Japan. Our IP position is therefore very strong," said Niels Emmerich, Managing Director and COO of immatics. "We will continue to expand our patent portfolio by filing patents for individual TUMAPs, our peptide-based products and our technologies in all major countries and pharma markets."
About IMA901
IMA901 is an off-the-shelf cancer vaccines consisting of multiple fully synthetic tumorassociated peptides (TUMAPs), representing tumor antigens relevant for renal cell carcinoma. IMA901 is currently in a European multi-center Phase II clinical trial. The TUMAPs contained in IMA901, were identified by analyzing the HLA peptide repertoire of a large number of primary tumor tissues and were selected based on their ability to activate TUMAP-specific cytotoxic T cells and T helper cells.
Press release Box-ID: 281220
immatics biotechnologies GmbH
Paul-Ehrlich-Str. 15
72076
Tübingen,
Germany
http://www.immatics.com
Contact
Ms
Katrin
Eckert
+49 7071 56512510
immatics biotechnologies GmbH
immatics biotechnologies is an independent biopharmaceutical company dedicated to the development of active immunotherapies against cancer. immatics' therapeutic vaccines are based on multiple tumor-associated peptides (TUMAPs) which specifically stimulate the immune system against cancer cells. Its lead products - IMA901 for the therapy of renal cell cancer and IMA910 for the treatment of colon cancer - are currently investigated in international phase II clinical studies. Since its foundation in 2000, immatics has raised more than €54 million (US$ 72million) in private equity in two financing rounds. The company has a headcount of more than 65 people and is based in Tuebingen and Munich, Germany.